FDA Approves Doptelet With Sprinkle Form for Pediatric Immune Thrombocytopenia

Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)

Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less than six years.

FDA Approves Doptelet With Sprinkle Form for Pediatric Immune Thrombocytopenia

Doptelet and new oral sprinkle granules is approved for children one year and older with chronic immune thrombocytopenia, showing 28% durable platelet response in study.